Estrogen replacement may protect against Alzheimer's disease in women

September 01, 2020

Biological sex influences the effect of amyloid beta on alterations to tau protein characteristic to Alzheimer's disease, suggesting a role for estradiol in preventing the disease in women, report scientists in the Journal of Alzheimer's Disease

Amsterdam, September 1, 2020-Alzheimer's disease (AD) is the most common neurodegenerative disease and the leading cause of dementia. It affects more women than men. A new study published in the Journal of Alzheimer's Disease indicates that factors such as age, reproductive stage, hormone levels, and the interplay with other risk factors should be considered in women and proposes a role for early menopausal estrogen replacement to protect against the development of AD.

"The risk of developing AD as well as its progression and severity are known to be very different in men and women," explained co-lead investigator Elena Tamagno, PhD, Department of Neuroscience and Neuroscience Institute of Cavalieri Ottolenghi Foundation (NICO), University of Torino, Torino, Italy. "Recent epidemiological studies showed that two thirds of AD patients are women, and this fact cannot be attributed only to their higher life expectancy. The loss of estradiol might be one of the factors leading to declining cognitive function in women."

Hallmarks of AD are the accumulation of amyloid beta peptides in amyloid plaques, and the aggregation of modified tau protein to form neurofibrillary tangles. Tau proteins are abundant in nerve cells and perform the function of stabilizing microtubules, and are pathologically altered in AD. To examine the hypothesis that biological sex influences the effect of amyloid beta 42 (AB42) peptides on these changes to tau protein, investigators gave intraventricular injections of nanomolecular concentrations of AB42 to transgenic mice expressing the wild-type human tau (hTau). In a previous study the investigators had noted that female mice did not show the alterations of tau protein characteristic of AD. In the current study they demonstrated that AB42 caused the pathological form of tau in ovariectomized female mice, but not in control females, and that estrogen replacement reversed this effect through an antioxidant activity and a decrease of tau phosphorylation.

"Our study indicates that factors such as age, reproductive stage, hormone levels, and the interplay with other risk factors should be considered in women, in order to identify the best appropriate treatment in prevention of cognitive impairment," commented co-lead investigator Massimo Tabaton, MD, Unit of Geriatric Medicine, Department of Internal Medicine and Medical Specialties (DIMI), University of Genova, Genova, Italy. "Our results suggest that an early postmenopausal estrogen replacement may be protective against AD."

"Linking estrogen deficiency to the tau changes of AD provides the missing mechanistic link to the greater risk of AD in women and significantly suggests therapeutic avenues to reduce AD," added George Perry, PhD, Editor-in-Chief of the Journal of Alzheimer's Disease and Semmes Foundation Distinguished University Chair in Neurobiology at The University of Texas at San Antonio.

AD is a major social and health problem. In the United States, approximately 5.5 million people are affected, and the number is growing as a result of the increase in life expectancy. The prevalence of dementia worldwide is estimated at 24 million people, which is expected to double by 2050. AD is characterized by progressive cognitive decline usually beginning with impairment in the ability to form recent memories, but inevitably affecting all intellectual functions and leading to complete dependence for basic functions of daily life and premature death. Women are more likely to develop the disease, independent of their longer life expectancy: one in six women over 65 develops AD, compared with one in 11 men.
-end-


IOS Press

Related Amyloid Beta Articles from Brightsurf:

Novel technique spotlights neuronal uptake of amyloid beta in Alzheimer's disease
One of the hallmarks of Alzheimer's disease is the formation of amyloid plaques that collect between neurons in the brain.

Amyloid deposits not associated with depression in the elderly
Researchers have suspected that Aβ deposits might also underlie the cognitive decline seen in older people with depression, however a new study from researchers at the University of California, San Francisco (UCSF) has found that abnormal Aβ deposits were actually found in fewer older adults with major depression compared to non-depressed control subjects.

Amyloid formation in the International Space Station
The collaborative research team of Japan using the International Space Station (ISS) successfully characterized Alzheimer's disease-related amyloid fibril formation under microgravity conditions.

New microscopy method provides unprecedented look at amyloid protein structure
Neurodegenerative diseases such as Alzheimer's and Parkinson's are often accompanied by amyloid proteins in the brain that have become clumped or misfolded.

Gold nanoparticles uncover amyloid fibrils
EPFL scientists have developed powerful tools to unmask the diversity of amyloid fibrils, which are associated with Alzheimer's disease and other neurodegenerative disorders.

How the historically misunderstood amyloid helps to store memories
For the first time, scientists from the Stowers Institute for Medical Research and collaborators have described the structure of an endogenously sourced, functioning neuronal amyloid at atomic resolution.

Scientists find functioning amyloid in healthy brain
The generation of amyloids, a special form of fibrillar proteins, is believed to result in Alzheimer's, Parkinson's and Huntington's diseases.

New mathematical model for amyloid formation
Scientists report on a mathematical model for the formation of amyloid fibrils.

What comes first, beta-amyloid plaques or thinking and memory problems?
The scientific community has long believed that beta-amyloid, a protein that can clump together and form sticky plaques in the brain, is the first sign of Alzheimer's disease.

The seeds of Parkinson's disease: amyloid fibrils that move through the brain
Researchers at Osaka University used microbeam X-ray diffraction to study the ultrastructure of Lewy bodies in post-mortem brains of Parkinson's disease patients.

Read More: Amyloid Beta News and Amyloid Beta Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.